Hikma Pharmaceuticals PLC Stock: price and insider trades · United Kingdom

This page follows insider dealings at Hikma Pharmaceuticals PLC as filed with RNS (LSE) based in London, United Kingdom. The group dates from 1978. 12 insiders have disclosed 42 filings since 20 October 2025.

No insider sold shares on the market over the period. Instead, the filings list 17 purchases totalling €10.3M, made by 7 insiders. The totals do not cover 10 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €5.7M, bought by Mazen Darwazah and made public on 7 November 2025. Those buying include 3 chief executives, 2 board members and 2 senior executives.

The data flag 13 purchases as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 10 August 2026, which is 72 days ago. Filings reach the RNS (LSE) feed a median of 2 days after the trade. Under the UK Market Abuse Regulation, managers have three business days to notify their trades.

With 42 filings in twelve months, the company is more active than the median of 6 filings across the 832 companies we follow on the same exchange. The full history, which starts in 2016, counts 49 purchases against 11 sales.

Elsewhere in the same market, our signals recently picked up insider purchases at CMC Markets plc. This summary is built from RNS (LSE) disclosures alone and does not predict where the share price will go.